TREM2-mTOR Co-Agonism for Metabolic Reprogramming
Target: TREM2-mTOR pathway
Composite Score: 0.511
Price: $0.51
Citation Quality: Pending
neurodegeneration
Status: proposed
✓ All Quality Gates Passed
Quality Report Card click to collapse
C+
Composite: 0.511
Top 38% of 628 hypotheses
T4 Speculative
Novel AI-generated, no external validation
Needs 1+ supporting citation to reach Provisional
C+
0.52
Top 79%
B
0.60
Top 55%
B+
0.70
Top 68%
F
0.22
Top 94%
B
0.65
Top 68%
F
0.18
Top 98%
D
0.35
Top 87%
B
0.60
Top 69%
C+
0.52
Top 71%
C
0.48
Top 78%
Evidence
7 supporting
|
6 opposing
Citation quality: 0%
Debates
1 session
B+
Avg quality: 0.72
Convergence
0.00
F
30 related hypothesis share this target
From Analysis:
TREM2 agonism vs antagonism in DAM microglia
The disease-associated microglia (DAM) phenotype involves TREM2 upregulation, but whether therapeutic agonism or antagonism of TREM2 is beneficial remains contested across disease stages.
Hypotheses from Same Analysis (6)
These hypotheses emerged from the same multi-agent debate that produced this hypothesis.
PLCG2 Allosteric Modulation as a Precision Therapeutic for TREM2-Dependent Microglial Dysfunction
Score: 0.636 | Target: PLCG2
TREM2-APOE Axis Dissociation for Selective DAM Activation
Score: 0.590 | Target: TREM2-APOE axis
TYROBP (DAP12) Conditional Antagonism for Early-Stage Neuroprotection
Score: 0.544 | Target: TYROBP
CSF1R-TREM2 Co-Agonism for Sustained Microglial Expansion
Score: 0.528 | Target: CSF1R-TREM2
CX3CR1-TREM2 Integration for Synapse Pruning Normalization
Score: 0.476 | Target: CX3CR1-TREM2
INPP5D (SHIP1) Inhibition to Shift Microglial Polarization
Score: 0.458 | Target: INPP5D
Description
Co-targeting TREM2 agonism with mTOR activation to restore metabolic competence, enabling proper DAM transition in TREM2 risk variant carriers
Figures & Visualizations
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
13 citations
6 with PMID
Validation: 0%
7 supporting / 6 opposing
✓
For
(7)
(6)
Against
✗
High
Medium
Low
High
Medium
Low
Evidence Matrix
— sortable by strength/year, click Abstract to expand
Evidence Types
MECH 12CLIN 1GENE 0EPID 0
Legacy Card View — expandable citation cards
✓ Supporting Evidence 7
TREM2 maintains microglial metabolic fitness in AD through mTOR signaling
TREM2-deficient microglia have defective mTOR signaling with abundant autophagic vesicles
Microglial mTOR activation upregulates Trem2 and enhances β-amyloid plaque clearance
STRING protein interaction: TYROBP-CSF1R (0.56)
STRING protein interaction: TREM2-CSF1R (0.402)
Enrichment: 'Regulation of primary metabolic process' (p=1.1e-06)
Enrichment: 'Positive regulation of membrane invagination' (p=6.3e-06)
✗ Opposing Evidence 6
mTOR activation inhibits autophagy; TREM2-deficient microglia accumulate autophagic vesicles but mTOR activati…▼
mTOR activation inhibits autophagy; TREM2-deficient microglia accumulate autophagic vesicles but mTOR activation may exacerbate this accumulation by blocking autophagic clearance
Metabolic reprogramming complexity—forcing mTOR activation may lock microglia in a pro-inflammatory glycolytic…▼
Metabolic reprogramming complexity—forcing mTOR activation may lock microglia in a pro-inflammatory glycolytic state incompatible with DAM transition
Residual microglia following short-term PLX5622 treatment exhibit diminished NLRP3 inflammasome and mTOR signa…▼
Residual microglia following short-term PLX5622 treatment exhibit diminished NLRP3 inflammasome and mTOR signaling, and enhanced autophagy—reducing mTOR may be beneficial
mTOR inhibitors (rapamycin) have been explored for longevity and neuroprotection with mixed results; direct mT…▼
mTOR inhibitors (rapamycin) have been explored for longevity and neuroprotection with mixed results; direct mTOR activation in the brain carries risks
No mTOR activators exist in the pharmaceutical pipeline; the hypothesis lacks a clear pharmacological strategy
The fundamental antagonism between mTOR activation and autophagy makes this hypothesis mechanistically fragile
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-01 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼
[Dry run - no API key]
🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼
[Dry run - no API key]
🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼
[Dry run - no API key]
⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼
[Dry run - no API key]
Price History
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0000
Events (7d)
1
Clinical Trials (0)
No clinical trials data available
📚 Cited Papers (4)
TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease.
Cell (2017) · PMID:28802038
No extracted figures yet
Microglial mTOR Activation Upregulates Trem2 and Enhances β-Amyloid Plaque Clearance in the
The Journal of neuroscience : the official journal of the Society for Neuroscience (2022) · PMID:35672148
No extracted figures yet
Residual microglia following short-term PLX5622 treatment in 5xFAD mice exhibit diminished NLRP3 inflammasome and mTOR signaling, and enhanced autophagy.
Aging cell (2025) · PMID:39571180
No extracted figures yet
Glucose Metabolic Reprogramming in Microglia: Implications for Neurodegenerative Diseases and Targeted Therapy.
Mol Neurobiol (2025) · PMID:39987285
No extracted figures yet
📓 Linked Notebooks (5)
📓 Top 5 Analysis: Sda 2026 04 01 Gap 001
Computational notebook for SDA-2026-04-01-gap-001
📓 SciDEX Analysis: 2026 04 01 Gap 001
Computational notebook for SDA-2026-04-01-gap-001
📓 TREM2 agonism vs antagonism in DAM microglia - Rich Analysis
TREM2/DAM analysis with expression plots, pathway enrichment, hypothesis scoring
📓 TREM2 agonism vs antagonism in DAM microglia
Analysis ID: SDA-2026-04-01-gap-001
📓 TREM2 agonism vs antagonism in DAM microglia
Analysis ID: SDA-2026-04-01-gap-001
Date: 2026-04-01
Domain: neurodegeneration
Key Hypotheses:
- TREM2-Dependent Microglial Senescence Transition (score: 0.705)
- Cell-Type Specific TREM …
KG Entities (22)
APOECSF1RCSF1R-TREM2CX3CR1CX3CR1-TREM2DAMDAP12INPP5DPLCG2SHIP1TREM2TREM2-APOE axisTREM2-mTOR pathwayTYROBPh-0cbe9bach-0f025d94h-2e03f316h-39148342h-5b378bd3h-7597968b
Related Hypotheses
TREM2-Dependent Microglial Senescence Transition
Score: 0.736 | neurodegeneration
SASP-Mediated Complement Cascade Amplification
Score: 0.734 | neurodegeneration
LRP1-Dependent Tau Uptake Disruption
Score: 0.716 | neurodegeneration
Nutrient-Sensing Epigenetic Circuit Reactivation
Score: 0.700 | neurodegeneration
Multi-Biomarker Composite Index Surpassing Amyloid PET for Treatment Response Prediction
Score: 0.696 | neurodegeneration
Estimated Development
Estimated Cost
$0
Timeline
0 months
🧪 Falsifiable Predictions
No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.
Knowledge Subgraph (31 edges)
associated with (7)
...and 2 more
co associated with (11)
...and 6 more
implicated in (6)
...and 1 more
targets (7)
...and 2 more
Mechanism Pathway for TREM2-mTOR pathway
Molecular pathway showing key causal relationships underlying this hypothesis
graph TD
h_2e03f316["h-2e03f316"] -->|targets| TREM2_mTOR_pathway["TREM2-mTOR pathway"]
TREM2_mTOR_pathway_1["TREM2-mTOR pathway"] -->|associated with| neurodegeneration["neurodegeneration"]
TREM2_mTOR_pathway_2["TREM2-mTOR pathway"] -->|implicated in| neurodegeneration_3["neurodegeneration"]
TREM2_mTOR_pathway_4["TREM2-mTOR pathway"] -->|co associated with| TREM2["TREM2"]
style h_2e03f316 fill:#4fc3f7,stroke:#333,color:#000
style TREM2_mTOR_pathway fill:#ce93d8,stroke:#333,color:#000
style TREM2_mTOR_pathway_1 fill:#ce93d8,stroke:#333,color:#000
style neurodegeneration fill:#ef5350,stroke:#333,color:#000
style TREM2_mTOR_pathway_2 fill:#ce93d8,stroke:#333,color:#000
style neurodegeneration_3 fill:#ef5350,stroke:#333,color:#000
style TREM2_mTOR_pathway_4 fill:#ce93d8,stroke:#333,color:#000
style TREM2 fill:#ce93d8,stroke:#333,color:#000
3D Protein Structure
🧬 TREM2-MTOR — Search for structure Click to search RCSB PDB
🔍 Searching RCSB PDB for TREM2-MTOR structures...
Querying Protein Data Bank API
Source Analysis
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration | 2026-04-01 | completed